RIYADH — In collaboration with King Saud University, Pfizer Saudi Arabia Ltd. has announced the organization of a two-day extensive training course starting today (July 16) for students from the university’s College of Pharmacy. The course is part of many programs organized by Pfizer in cooperation with different Saudi universities with the objective to contribute to developing and qualifying Saudi students as well as enhancing their pharmaceutical skills. The programs come within the company’s efforts to effectively participate in the realization of the objectives of Vision 2030.
Relying on the company’s considerable scientific expertise in the global pharmaceutical manufacturing industry, the training course will be offered by international experts and specialists from Pfizer with the aim to develop this vital sector in the Kingdom.
General Manager of Pfizer Saudi Arabia Ltd. Dr. Alaa Abdul Ghani explained that the course intends to empower Saudi pharmacy students and enrich them with practical and scientific experience that can enable them to work in the pharmaceutical sector and contribute to building their communities and nation. “At Pfizer we have used practical methods to express our commitment towards the Saudi community as well as our vision to contribute to the realization of Vision 2030; which is particularly concerned with employing Saudi youth. In this context, we launched this program to collaborate with colleges of pharmacy across the Kingdom,” he added.
Dean of the College of Pharmacy at King Saud University Dr. Aws bin Ibrahim Al Shamsan expressed his appreciation to Pfizer for taking initiative by organizing this imperative course and inviting international experts to enrich the Kingdom’s pharmaceutical industry by transferring their knowledge to Saudi students. He revealed that this program is the first of more pharmaceutical training programs to come in cooperation with different partners and sectors.
In early 2017, Pfizer Saudi Arabia Ltd. opened its new integrated plant at King Abdullah Economic City with an investment value exceeding 50 million USD. The plant aims to manufacture Pfizer products locally and transfer expertise, technologies, and trained personnel to the Kingdom. The new plant contributes to the provision of medications for different categories of patients, and also creates the opportunity to develop industrial expertise and qualify local competencies to manufacture drugs inside the Kingdom.
Pfizer Saudi Arabia Ltd., which falls under its parent company located in the United States, has been operating in the Kingdom of Saudi Arabia since the 1960s. Throughout the years, the company has contributed to the development of the Kingdom’s healthcare industry by developing and innovating high quality drugs, promoting the importance of healthcare, raising awareness of different diseases, and offering prevention solutions in cooperation with relevant government agencies and healthcare institutions from both the public and private sectors. — SG
